Inventor · disambiguated record
Wen Fury
Also filed as: FURY WEN
10 granted patents·6 pending applications·17 citations·filing 2009–2024
84Inventor score
Top patents by PatentIndex Score
16 records- 0195US11845931B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·4 cites·37 claims
- 0295US11845930B2Methods and systems for CRISPR selectionREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·4 cites·23 claims
- 0393US12209238B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2023·Granted Jan 28, 2025·1 cites·42 claims
- 0490US10851158B2Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 1, 2020·4 cites·27 claims
- 0588US12421512B2CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregationREGENERON PHARMA·Filed 2024·Granted Sep 23, 2025·0 cites·32 claims
- 0680US2024182887A1Methods and systems for crispr selectionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0774US10162933B2High resolution allele identificationREGENERON PHARMA·Filed 2014·Granted Dec 25, 2018·2 cites·24 claims
- 0870US8255167B2Non-hypergeometric overlap probabilitySWAMINATHAN KARTHIKEYAN·Filed 2009·Granted Aug 28, 2012·2 cites·9 claims
- 0963US11594302B2High resolution allele identificationREGENERON PHARMA·Filed 2018·Granted Feb 28, 2023·0 cites·27 claims
- 1060US2023293727A1Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathyREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1160US2024185953A1Systems and methods for high-throughput predictionsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1256US2012323497A1Non-Hypergeometric Overlap ProbabilitySWAMINATHAN KARTHIKEYAN·Filed 2012·Application pending·0 cites
- 1354US2021142867A1Accurate And Robust Information-Deconvolution From Bulk Tissue TranscriptomesREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1452US2021403567A1Methods of treating cervical cancer by administering a pd-1 inhibitorREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1550US10083274B2Non-hypergeometric overlap probabilityREGENERON PHARMA·Filed 2017·Granted Sep 25, 2018·0 cites·22 claims
- 1650US10005834B2Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereofREGENERON PHARMA·Filed 2016·Granted Jun 26, 2018·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when Wen Fury files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →